Skip to search formSkip to main contentSkip to account menu

cabozantinib

Known as: 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide 
An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (2)

AnilidesPyridines

Narrower (5)

BMS 907351CabometyxCometriqXL 184
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitioncabozantinib 60 MG Daily Dose, 20 MG Oral Capsule 84 Count Packcabozantinib 60 MG Oral Tablet [Cabometyx]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.
139Background: C may enhance response to immune checkpoint inhibitors by promoting an immune-permissive microenvironment. COSMIC… 
2019
2019
Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor…
Review
2016
Review
2016
Systemic treatment and management approaches for medullary thyroid cancer.
2015
2015
Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
The dermatologic adverse events (AEs) of various molecularly targeted therapies are well‐described in adult cancer patients… 
2014
2014
Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its… 
2013
2013
Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein
Highly Cited
2013
Highly Cited
2013
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed. It is often… 
Review
2013
Review
2013
Reducing the burden of bone metastases
BackgroundBone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are… 
2012
2012
Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
2012
2012
Flubendiamide Transport Through Packed Soil Columns
Flubendiamide insecticide is widely used in Indian subtropical condition to control lepidopteron pests mainly in rice and cotton… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)